Surrozen (SRZN) Share-based Compensation (2020 - 2026)
Surrozen (SRZN) posted quarterly Share-based Compensation of $37.3 million for Q1 2026, up 4372.42% year-over-year from $834000.0 in Q1 2025, and up 3622.55% quarter-over-quarter from $1.0 million in Q4 2025.
Surrozen (SRZN) Share-based Compensation (2020 - 2026) Analysis & Trends
Surrozen's Share-based Compensation history runs 7 years deep, the most recent figure standing at $37.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 4372.42% year-over-year to $37.3 million; the TTM figure through Mar 2026 stood at $37.3 million (up 852.02% YoY), while the FY2025 annual figure was $8.1 million, up 96.89% from the prior year.
- Share-based Compensation for Q1 2026 stood at $37.3 million, up from $1.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $37.3 million in Q1 2026, with the low at $834000.0 in Q1 2025.
- The 5-year median for Share-based Compensation is $1.0 million (2024), against an average of $3.2 million.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation fell 24.14% in 2023, then jumped 4372.42% in 2026.
- Surrozen's Share-based Compensation stood at $1.5 million in 2022, then dropped by 24.14% to $1.2 million in 2023, then decreased by 23.21% to $900000.0 in 2024, then advanced by 11.33% to $1.0 million in 2025, then surged by 3622.55% to $37.3 million in 2026.
- Business Quant data shows SRZN's Share-based Compensation at $37.3 million in Q1 2026, $1.0 million in Q4 2025, and $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 35.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.30 Mn |
| Jun 30, 2026 | 35.30 Mn |
| Mar 31, 2026 | 37.30 Mn |
| Mar 31, 2026 | 37.30 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 994,000.00 |
| Jun 30, 2025 | 994,000.00 |
| Mar 31, 2025 | 834,000.00 |
| Mar 31, 2025 | 834,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Sep 30, 2024 | 1.04 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |